DRTS Stock Forecast & Price Target

Alpha Tau Medical has made significant progress by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, marking a key operational milestone as it prepares to begin manufacturing its proprietary Alpha DaRT technology in the U.S. by 2026. The company is positioned with a strong cash reserve, which supports its ongoing development and commercialization efforts in the oncology sector, specifically targeting solid tumors with a potentially groundbreaking treatment method. Although the company reported a net loss of $11.7 million, this figure was only moderately higher than expectations, indicating manageable financial performance as it advances toward its operational goals.

Alpha Tau Medical reported a net loss of $11.7 million for the third quarter of 2025, indicating significant financial strain during this period. The company's prospects are clouded by considerable risks, including the potential failure of its AlphaDaRT technology in clinical trials and the challenges in securing regulatory approval in the U.S. Additionally, market competition, size limitations, and possible dilution risks further undermine the likelihood of achieving commercial success, contributing to a negative outlook on the stock.